Melbourne (Australia) – 27th December 2019. Telix Pharmaceuticals Limited (ASX: TLX), is pleased to announce that it has submitted a comp...

Melbourne (Australia) – 14 October 2019. Telix Pharmaceuticals Limited (ASX:TLX, “Telix”, the “Company”) a clinical-stage biopharmaceutic...

TLX591-CDx (68Ga-PSMA) for the imaging of prostate cancer with positron emission tomography (PET).

Program relevance: TLX591-CDx (68Ga-PSMA-11) for the imaging of metastatic prostate cancer with positron emission tomography (PET) Synops...

Program relevance: TLX591-CDx (68Ga-PSMA) for the imaging of prostate cancer with positron emission tomography (PET). Branded as illumetT...

TLX591-CDx (68Ga-PSMA) for the imaging of prostate cancer with positron emission tomography (PET). Branded as illumetTM in the US market.

Date: 26th April, 2019 Program relevance: TLX591 (Prostate Therapy), TLX591-CDx (Prostate Imaging) Synopsis: The development of TLX591 is...

Program relevance: TLX591 Synopsis: In conjunction with the completion of the acquisition of Atlab Pharma SAS (ASX release: 11/09/18) Tel...

Melbourne (Australia) and Nantes (France) – 11 September 2018. Telix Pharmaceuticals Limited (“Telix”, the “Company”) today announced the...